Relive Greens from The Root Brands: The Key to Gut Health and Digestion in 2025
Franklin, Tennessee--(Newsfile Corp. - June 17, 2025) - As gut health and digestion take center stage in 2025's health and wellness trends, The Root Brands proudly presents Relive Greens as the ultimate solution to support a healthy digestive system. With 83% of Americans recognizing the critical role of gut health in overall well-being, Relive Greens is expertly formulated to meet this growing demand.
Why Gut Health Matters
Recent studies reveal that 22% of Americans are prioritizing gut health and digestion as part of their wellness journey. Despite this focus, many remain unaware of how probiotics and nutrient-dense foods can dramatically enhance their digestive health. Poor gut health is linked to numerous issues, including low energy, weakened immunity, and mental health challenges, emphasizing the importance of effective solutions.
Relive Greens: A Comprehensive Solution
Relive Greens stands out as a premium superfood blend designed to nourish and balance the digestive system. By combining the power of:
Relive Greens helps address common gut health challenges and empowers individuals to feel their best.
'Gut health is foundational to overall health,' said Dr. Christina Rahm, Chief Science Formulator of The Root Brands. 'With Relive Greens, we provide an easy and effective way for people to support their digestion, boost their immunity, and enhance their vitality.'
Backed by Science
Relive Greens is a scientifically crafted blend tailored to improve gut health from the root. The formula's unique combination of probiotics and detoxifying greens works synergistically to:
Availability
Relive Greens is available through The Root Brands' website. It's vegan, non-GMO, and free from artificial additives, ensuring that anyone can enjoy its benefits as part of their daily wellness routine.
About ROOT Wellness:
ROOT Wellness is a social sharing community committed to helping people achieve optimal health through detoxification, supplementation, and lifestyle changes. Founded by Clayton Thomas, the company empowers individuals to take control of their well-being through education, innovative products, and a supportive network.
#therahmeffect
The most important environment is YOURS!
R Public Relations
[email protected]
518-321-3906
We do not claim or imply our products prevent, treat, or cure any illness, disorder, or disease. We focus on the ROOT cause to support your pathway to create Greatness.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255870
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
32 minutes ago
- Medscape
Q&A: New Myeloma Bispecific Rivals CAR T in Early Data
CHICAGO — Two early-phase clinical trials released data at the American Society of Clinical Oncology (ASCO) 2025 annual meeting that suggest their premise — an elranatamab-based triplet regimen and a new trispecific regimen — shows good potential in multiple myeloma (MM). 'It was interesting to see where these new lines of thought will take us in treating myeloma. Elranatamab is already approved in the third-line setting in the US, and using it in the frontline setting in MagnetisMM-6 shows promise,' said oral abstract session discussant Amrita Krishnan, MD, of the City of Hope Comprehensive Cancer Center in Duarte, California. 'And the first-in-human data from JNJ-5322 shows the drug has incredible activity.' 'In both these trials, we need to see if their responses hold,' Krishnan added. Early MagnetisMM-6 Readout The key takeaway from MagnetisMM-6 Part 1, dose level G, is that initial data show that the triplet combination of elranatamab with daratumumab and lenalidomide is effective and manageable in patients with newly diagnosed MM who are not eligible for transplant. That's according to study author Hang Quach, MD, of St Vincent's Hospital Melbourne, University of Melbourne, in Melbourne, Australia. Elranatamab is a B-cell maturation antigen (BCMA)-CD3 bispecific antibody approved as a late-line monotherapy in relapsed or refractory multiple myeloma. Quach and co-authors hypothesized that adding daratumumab and lenalidomide may enhance immune cell-mediated myeloma cell death. MagnetisMM-6 enrolled 37 patients with transplant-ineligible newly diagnosed MM. Of these, 34 received the triplet regimen. At data cutoff, the median follow-up was 7.9 months, and 32 patients were still on treatment. 'The combination showed early and promising efficacy, and we expect responses to deepen with longer follow-up,' Quach said. Quach reported that the safety profile was predictable and consistent with the components' known toxicities. Treatment-related adverse events were seen in more than 50% of patients. The most common were hematologic AEs, infections, and cytokine release syndrome (CRS). All CRS events were grade 2 or less, and one grade 2 immune effector cell-associated neurotoxicity syndrome event occurred. The phase 3 MagnetisMM-6 Part 2 trial, which will open soon, will evaluate the same elranatamab triplet combination against daratumumab plus lenalidomide plus dexamethasone in transplant-ineligible and transplant-deferred patients with newly diagnosed MM. The study design is patient-centric regarding dosing frequency and de-escalation, Quach said: 'There will be a response-adapted scheduling modification upon achievement of complete response after 12 months at least.' JNJ-5322: First-in-Human Trial The first-in-human trial of JNJ-5322, a BCMA- and GPRC5D-targeted T-cell redirecting trispecific antibody, enrolled 147 patients. 'We treated these patients with different doses and at different dosing schedules and defined the recommended phase 2 dose (RP2D) as 100 mg administered every 4 weeks subcutaneously with only one step-up dose,' said Niels W.C.J. van de Donk, MD, PhD, of Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. 'At the RP2D, we see a manageable safety profile with improved or similar GPRC5D-related adverse events.' As expected, infections were common. The grade 3 or 4 infection rate was 28.6% with prophylactic infection management. GPRC5D-related oral side effects were also observed in the study. Taste-related changes were observed in 60% of patients, while other non-taste-related oral AEs were less frequent and included dry mouth, dysphagia, stomatitis, and decreased appetite. 'The frequency and severity of these oral adverse events is lower than what is typically seen,' van de Donk said. 'And this milder oral treatment emergent AE profile is also reflected in that only 6% of the patients had a transient weight loss of grade 1 or grade 2.' Among patients naive to BCMA- and GPRC5D-targeted therapies and treated at the RP2D, the investigators observed a 100% response rate, a complete response (CR) rate of 70%, and at least a very good partial response in 96%. 'And this deep response translates into a promising progression-free survival of 95% at 1 year,' van de Donk said. 'Overall, JNJ-5532 demonstrated a manageable safety profile and an overall response rate comparable to CAR [chimeric antigen receptor] T with convenient off-the-shelf every 4 weeks dosing with one step-up dose to facilitate outpatient dosing.' Following this presentation, Krishnan sat down with Medscape Medical News . The following interview has been edited for clarity. What is the premise of the MagnetisMM-6 trial? The rationale for using elranatamab in the upfront, newly diagnosed setting is that, in a newly diagnosed myeloma, you probably have healthier T cells than a patient with heavily pretreated disease. The hope is that this drug may work even better in this setting. What stood out to you about MagnetisMM-6's trial design? Participants had a median age of 75 years, which is old for a trial, and 24% of them were frail, which is also quite notable. Patients had a very deep response, which is encouraging in this newly diagnosed setting. The approved dose of elranatamab is weekly, but the investigators gave it only once every 4 weeks, which may be in part why they had a much more favorable safety profile in terms of risk for infection. What will you be watching for from MagnetisMM-6? The data looked promising, but the follow-up is very short. On this trial it's about 7.9 months, so we really need to see if the responses hold and how deep the responses are. What is the premise of the JNJ-5532 trial? The drug targets both GPRC5D and BCMA, with the idea being that, if you hit both targets at once, maybe your response rates are higher than hitting just one target, and that appears to be the case. The reported response rates of 100% are certainly dramatic, but the follow-up right now is very short. What stood out to you about JNJ-5532? With most of the bispecifics, the response rates are about 60%-70%. Now we're looking at a response rate that's close to CAR T-cell therapy for the first time, and it's frankly incredible. But the attractive thing with CAR T has always been 'one and done' vs staying on treatment for a fixed duration or even indefinitely. If you're still having to give patients a drug for, say, 5 years, that's probably not as attractive. Is JNJ-5532 likely to be better tolerated than CAR T? We haven't seen any neurologic toxicity yet, so that's encouraging. And the logistics, of course, are much easier. With JNJ-5532, you get one step-up dose, and it can be given outpatient. So, the comparison with CAR T is not just about side effects: The whole burden of care is very different, and the ability to get it in the community versus entirely inpatient is another big issue in terms of access. MagnetisMM-6 was funded by Pfizer. Quach disclosed relationships with Antengene (Inst), Amgen, Bristol Myers Squibb/Celgene, Celgene, GlaxoSmithKline (Inst), Janssen-Cilag, Karyopharm Therapeutics (Inst), Pfizer, roche, and Sanofi (Inst). JNJ-5532 was funded by Johnson & Johnson. van de Donk reported ties with Adaptive Biotechnologies (Inst), Amgen (Inst), Bayer (Inst), Bristol Myers Squibb Foundation (Inst), Celgene (Inst), Cellectis (Inst), Janssen (Inst), Merck (Inst), Novartis (Inst), Roche (Inst), Servier (Inst), and Takeda (Inst).
Fox News
37 minutes ago
- Fox News
Senators Ricketts, Fetterman unite against China's quiet invasion of US farmland
EXCLUSIVE: Republican Sen. Pete Ricketts is leading the charge with Democrat Sen. John Fetterman to codify oversight on foreign countries buying American farmland. The bipartisan Agricultural Foreign Investment Disclosure (AFIDA) Improvements Act seeks to implement recommendations published by the Government Accountability Office (GAO) in January 2024, which found the AFIDA was ill-equipped to combat foreign ownership of American agricultural land. "Communist China is our greatest geopolitical threat," Ricketts told Fox News Digital in an exclusive interview, adding, "This is a way for us to improve the disclosure that's going on with regard to the purchase of this agricultural land, so we can take other action if necessary to make sure we're not giving Communist China the opportunity to buy agricultural land." The bill's proposal comes as two Chinese nationals – a University of Michigan post-doctoral research fellow, Yunqing Jian, and Huazhong University of Science and Technology student Chengxuan Han – were held in federal custody after they were accused of smuggling biological materials into the United States. The suspects have been charged with "smuggling a fungus that has been described as a "potential agroterrorism weapon" into the heartland of America, where they apparently intended to use a University of Michigan laboratory to further their scheme," interm U.S. Attorney for the Eastern District of Michigan Jerome Gorgon said in a statement. The fungus causes a "head blight," described as a disease of wheat, maize, rice and barley, and is responsible for billions of dollars of economic losses throughout the world each year, according to the Department of Justice. If ingested by humans, the substance can cause vomiting, liver damage and "reproductive defects in humans and livestock." Department of Homeland Security Assistant Secretary Tricia McLaughlin told Fox News Digital that the Trump administration is focused on "keeping our homeland secure" through enhanced border screenings. "Protecting America's food supply and national security remains a top priority. Last week's smuggling attempt by Chinese nationals of Fusarium graminearum, a dangerous crop-destroying fungus, posing a significant bioterrorism threat, only highlights this imperative to combat this threat," McLaughlin said. "That could potentially be very damaging to agriculture," Ricketts told Fox News Digital. "We also know that Chinese nationals have been trying to steal our biotechnology with regard to agriculture. They've also been crashing gates of bases. Supposed Chinese tourists have been flying drones around bases. Of course, the Chinese flew a surveillance balloon over our country when the Biden administration just let that happen." Ricketts said China has been aggressively buying American agriculture, "which is why we need to have a heightened sense of vigilance around protecting our homeland." Foreign investors own over 40 million acres of agricultural land in the United States, and between 2010 and 2021, Chinese ownership of American agricultural land increased from 13,720 acres to 383,935 acres, according to the U.S. Department of Agriculture (USDA). "It's not just about the number of acres that they own, but the fact that they own it around Grand Forks Air Force Base in North Dakota or Fort Liberty in North Carolina. They're buying it around sensitive military installations," Ricketts said. The bill, also co-sponsored by Sens. Tommy Tuberville of Alabama, John Cornyn of Texas, Roger Wicker of Mississippi and Rep. Don Bacon of Nebraska, requires AFIDA reporting for foreign persons holding more than 1% interest in American agricultural land. The AFIDA Improvements Act aims to increase information-sharing between the Committee on Foreign Investment in the United States and the USDA. It also requires updates to the AFIDA's handbook and establishes a deadline for USDA to set up an online AFIDA system. Based on the GAO's recommendations, the bill seeks to update the Agricultural Foreign Investment Disclosure Act of 1978 to better equip the USDA to combat foreign adversaries' ownership of American agricultural land. "We are at the most dangerous point in our history right now since World War II," Ricketts said. "We have to be investing in our military. We have to be supporting our friends around the world that are pushing back on these dictators. Communist China is one of them." Additionally, the bill comes as conflict in the Middle East reaches a boiling point between Iran and Israel, reigniting concerns about national security. Israel successfully coordinated attacks against Iran from inside the country, and Ricketts pointed to Ukraine's success in targeting a Russian air base. "What Ukraine was able to do against Russia with their operation that destroyed some of their strategic bombers, and they placed trucks with drones close to an air base and had those drones attack their squadrons. We could be vulnerable to the same thing if China did that here. They've owned farmland close enough to our air bases to be able to launch a drone strike. That should be very concerning to us," Ricketts said. Ricketts added that American farmland should not be a "tool that our adversaries, like Communist China, can use to attack us from inside our own country." There has been little movement on the bill since it was just recently introduced. That is largely because Senate Republicans are narrowly focused on advancing Trump's "big, beautiful bill" ahead of a self-imposed July 4 deadline.
Fox News
38 minutes ago
- Fox News
Republicans demand answers on blue state health program accused of leaking patient data to Big Tech
FIRST ON FOX: House Republicans are putting California's state-run public health insurance exchange on notice with a letter demanding answers about its leaking of private patient data to third-party entries as part of a marketing effort. Spearheaded by several Republicans on the House Energy and Commerce Committee, the letter to Covered California, which facilitates public health insurance for millions of Californians, seeks answers to numerous questions about its alleged leak of private patient data to third-party entities, such as LinkedIn and Google. "Ensuring the confidentiality of health information is a foundational obligation for entities operating within the health insurance ecosystem," the letter, signed by five Republican leaders in the House, states. It points out how federal privacy protections, in particular those stemming from the Health Insurance Portability and Accountability Act (HIPAA), establish certain "expectations" for how organizations like Covered California must handle patient information. Additionally, in California, the law requires consumers provide permission to certain organizations before their medical information can be disclosed to third-parties. "Recent reports and public filings raised questions about whether those expectations were met in this case, and whether existing oversight mechanisms are sufficient to detect and prevent improper disclosures," the Republicans' letter asserted. Following public criticism in late April, alleging that Covered California was passing sensitive patient data to LinkedIn via a network of "trackers" on its website, the state-run health insurance exchange removed them. The criticism stemmed from a forensic analysis by two investigative nonprofits, which found Covered California's website was sharing patients' answers to questions, such as whether one is pregnant, or how many prescription drugs they use, or how often they see doctors, were being passed to LinkedIn without the patients' knowledge or consent. Other questions included demographic information and other sensitive personal data, and Covered California subsequently admitted to sharing patients' Social Security numbers. In total, Covered California had more than 60 active "trackers" on various data points, according to Cal Matters, one of the investigative nonprofits that uncovered the leaked data. Cal Matters, in their investigation, pointed out how the average number of trackers across more than 200 government websites it investigated was only three. Following the Cal Matters report that led to public criticism, Coverd California subsequently explained that the "trackers" it had functioning on its website were part of an advertising campaign initiated in February 2024, and upon discovery of the data sharing, it removed them in April the following year. "Covered California leverages LinkedIn's advertising platform tools, including LinkedIn Insight tags, which are pieces of code added to a website to help track how visitors interact with the site. This tool allows us to better understand consumer behavior and deliver tailored messages to help consumers make informed decisions about their health care options," Covered California said in a public statement put out following the Cal Matters report. "While the review is still ongoing, Covered California has identified that some sensitive data was inadvertently collected by the tags, including first names, the last four digits of Social Security numbers, and other sensitive health information like pregnancy status." The state health insurance exchange added that it was reviewing its entire website to ensure no more analytical tools were improperly collecting or sharing sensitive patient data. Meanwhile, days after Cal Matters brought the data-sharing concerns involving Covered California to light, a class-action lawsuit was filed against LinkedIn and Google, accusing the companies of operating software enabling them "to intercept sensitive and confidential communications of Covered California customers." The letter from House Republicans marks the latest attempt to increase pressure on the California-run public health insurance exchange. Republicans are demanding answers to questions pertaining to its data sharing, including during the period of time it was allegedly sharing info with LinkedIn, as well as questions about what Covered California is currently doing to protect its patients' data. "Americans deserve to know that their sensitive health data is secure and being handled prudently," Chairman Guthrie said following transmission of the letter to Covered California. "We are hopeful that California will be transparent and forthcoming about this apparent data security failure as we launch our investigation." "The unauthorized sharing of private health data with third-party advertisers— including pregnancy status, prescription drug use, and Social Security information— is deeply troubling," added California Rep. Jay Obernolte, a fellow Republican on the House Energy and Commerce Committee who helped spearhead the letter to Covered California alongside Guthrie. "We're seeking answers because the people of California deserve accountability and transparency when their privacy is compromised." When reached for comment, Covered California acknowledged receipt of the letter from Guthrie, Obernolte, and others on the House Energy and Commerce Committee, adding that they were currently reviewing its requests and plan to respond by the provided July 1 deadline. Google and LinkedIn declined to provide comment for this article.
